This study looks at a treatment called sacituzumab tirumotecan on its own and with another medicine called pembrolizumab. It is for people with a specific type of breast cancer that can't be removed by surgery or has spread to other parts of the body. These breast cancers are called HR+/HER2-, meaning they respond to hormones but not to treatments that target a protein called HER2. The study wants to see if these treatments work better than the usual treatments chosen by doctors. The main goal is to see if these treatments can help stop the cancer from growing for a longer time, which is called progression-free survival (PFS).

• The study involves trying new treatments, which might work better than current options.
• Participants must have specific types of breast cancer and meet certain health conditions.
• There may be risks or side effects, as with any cancer treatment.